IDXX
Idexx Laboratories · Health Care
9.3%
typical move (median |reaction| of last 8)
2026-11-02 pre · likely
next expected · estimated from pattern
13
scored events
Last eight reactions
2024-10-31 → 2026-08-04
| date | session | reaction | |move| | excess 5s | excess 20s |
|---|---|---|---|---|---|
| 2026-08-04 | pre | +3.6% | 3.6% | -0.1% | -6.1% |
| 2026-05-05 | pre | -0.0% | 0.0% | -7.1% | -4.5% |
| 2026-02-02 | pre | -4.7% | 4.7% | +0.3% | +1.6% |
| 2025-11-03 | pre | +14.4% | 14.4% | -1.5% | +1.6% |
| 2025-08-04 | pre | +27.5% | 27.5% | -5.2% | -7.9% |
| 2025-05-01 | pre | +8.9% | 8.9% | +2.8% | +3.4% |
| 2025-02-03 | pre | +11.2% | 11.2% | -2.1% | -2.4% |
| 2024-10-31 | pre | -9.7% | 9.7% | +1.6% | -2.2% |
Source filings
2026-08-04 · 8-K press release
IDEXX Laboratories Announces Second Quarter Results ▪ Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10%
2026-05-05 · 8-K press release
IDEXX Laboratories Announces First Quarter Results ▪ Achieves first quarter revenue growth of 14% as reported and 11% organic, and CAG Diagnostics recurring revenue growth of 14% as reported and 11% o
2026-02-02 · 8-K press release
IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results ▪ Achieves fourth quarter revenue growth of 14% as reported and 12% organic, reflecting strong CAG Diagnostics recurring revenue,
2025-11-03 · 8-K press release
IDEXX Laboratories Announces Third Quarter Results ▪ Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% o
2025-08-04 · 8-K press release
Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results · Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG
2025-05-01 · 8-K press release
Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results · Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Di
2025-02-03 · 8-K press release
Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results ▪ Achieves fourth quarter revenue growth of 6% as reported and on an orga
2024-10-31 · 8-K/A press release
Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Third Quarter Results ▪ Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Di